<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;C01B&quot;,&quot;href&quot;:&quot;atc/C01B.md&quot;},{&quot;label&quot;:&quot;tocainide&quot;}]"></div>

# tocainide

- **generic name:** tocainide
- **ATC codes:** `C01BB03`
- **DrugBank:** [DB01056](https://go.drugbank.com/drugs/DB01056) · **PubChem:** [CID 38945](https://pubchem.ncbi.nlm.nih.gov/compound/38945)
- **molar mass:** 192.2575 g/mol (C11H16N2O) — DrugBank
- **groups:** approved, withdrawn

## About

Tocainide is a class Ib antiarrhythmic that was used to treat heart arrhythmia and was also studied for trigeminal neuralgia. It has been withdrawn and is no longer in use.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q757058](https://www.wikidata.org/wiki/Q757058) and the WHO ATC classification; not checked by a person.</small>

## Molecules and molar masses

> The molar mass each model uses to convert mass to molar concentration and to form a metabolite molecule for molecule. Looked up, never estimated: DrugBank for the drug, the paper's own value or the PubChem entry matched to the paper's name for a metabolite.

| molecule | role | molar mass (g/mol) | formula | source | PubChem | records |
|---|---|---|---|---|---|---|
| tocainide | parent | 192.257 | C11H16N2O | DrugBank | [38945](https://pubchem.ncbi.nlm.nih.gov/compound/38945) | Lalka_1976 |

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-06 05:11 | 10:18 | 0/1/1 | 3/0/0 | 0/0/0 | 213,605/26,553 | ollama / qwen3.8:27b-mtp-q8_0 | 4 | 4/0 | 4/0 | 0 |

## popPK records

| status | detail | model | model structure | params | citation | doi |
|---|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--orange">needs review</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.364). The first reading is what the record holds.">cross-check: disputed</span><br><sub>blocking: C6_cl_magnitude failed (ratio None)</sub><br><sub>route_to: `human_review`</sub> | [Winkle_1976_reference](drugs/drug_tocainide/Tocainide_Winkle1976_reference.md) | — | 1-compartment (no model) | 2 | Winkle RA et al., Clinical efficacy and pharmacokinetics…, Circulation (1976) | [10.1161/01.cir.54.6.885](https://doi.org/10.1161/01.cir.54.6.885) |
| <span class="pk-badge pk-badge--red">rejected</span> <span class="pk-badge pk-badge--stale">stale</span> <span class="pk-badge pk-badge--red" title="re-read by gpt-oss:120b (not confirmed, agreement 0.188). The first reading is what the record holds.">cross-check: disputed</span><br><sub>STALE — current validate: rejected</sub><br><sub>blocking: C5 dimension mismatch on a structural parameter</sub><br><sub>route_to: `human_review`</sub> | [Lalka_1976_reference](drugs/drug_tocainide/Tocainide_Lalka1976_reference.md) | — | 1-compartment (no model) | 6 | Lalka D et al., Kinetics of the oral antiarrhythmic lid…, Clinical pharmacology and t… (1976) | [10.1002/cpt1976196757](https://doi.org/10.1002/cpt1976196757) |

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--species" title="Animal study (pig), not measured in people (from keyword rules on the title and abstract — no LLM answer yet).">pig</span> | [Dzimiri_1991_Na_K_ATPase_activity](drugs/drug_tocainide/pd_Dzimiri_1991_Na_K_ATPase_activity.md) | Na(+)-K(+)-ATPase activity ← tocainide · direct sigmoid Emax (Hill) effect | — | Dzimiri N et al., Comparative effects of procainamide, to…, General pharmacology (1991) | [10.1016/0306-3623(91)90472-i](https://doi.org/10.1016/0306-3623(91)90472-i) |
| <span class="pk-badge pk-badge--green">extracted</span> <span class="pk-badge pk-badge--species" title="Animal study (pig), not measured in people (from keyword rules on the title and abstract — no LLM answer yet).">pig</span> | [Dzimiri_1993_2_LDH](drugs/drug_tocainide/pd_Dzimiri_1993_2_LDH.md) | mitochondrial lactate dehydrogenase activity ← tocainide · direct sigmoid Emax (Hill) effect | — | Dzimiri N et al., Investigation of class I anti-arrhythmi…, Clinical and experimental p… (1993) | [10.1111/j.1440-1681.1993.tb01671.x](https://doi.org/10.1111/j.1440-1681.1993.tb01671.x) |
| <span class="pk-badge pk-badge--green">extracted</span> | [Meffin_1977_antiarrhythmic_response](drugs/drug_tocainide/pd_Meffin_1977_antiarrhythmic_response.md) | antiarrhythmic response ← tocainide · stimulation effect | — | Meffin PJ et al., Response optimization of drug dosage: a…, Clinical pharmacology and t… (1977) | [10.1002/cpt197722142](https://doi.org/10.1002/cpt197722142) |

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=tocainide) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| distribution | blood | `ALB` other/unknown | DrugBank actor |
| metabolism | liver | `CYP1A2` inhibitor/substrate | DrugBank actor |

<sub>Actors without a tissue in the table: SCN5A (inhibitor).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 96 matched, 68 returned
- **screened:** 12  ·  **relevant:** 12
- **records:** 2  ·  extracted 0  ·  needs_review 1  ·  rejected 1  ·  stale 1
- **scholar-agent fallback query used:** True

## Full text wanted

_24 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Graffner_1980.pdf` | Graffner C et al., Tocainide kinetics after intravenous an…, Clinical pharmacology and t… (1980) | popPK | 10 | [10.1038/clpt.1980.10](https://doi.org/10.1038/clpt.1980.10) | [7351118](https://pubmed.ncbi.nlm.nih.gov/7351118) | The abstract explicitly reports quantitative PK parameters including half-life, volume of distribution, and renal clearance for tocainide in humans. |
| `Lalka_1976.pdf` | Lalka D et al., Kinetics of the oral antiarrhythmic lid…, Clinical pharmacology and t… (1976) | popPK | 10 | [10.1002/cpt1976196757](https://doi.org/10.1002/cpt1976196757) | [1269216](https://pubmed.ncbi.nlm.nih.gov/1269216) | The abstract explicitly reports quantitative pharmacokinetic parameters for tocainide in humans, including central volume (0.92 L/kg), total body clearance (166 ml/min), and half-life (11 hr). |
| `McErlane_1990.pdf` | McErlane KM et al., Stereoselective pharmacokinetics of toc…, European journal of clinica… (1990) | popPK | 10 | [10.1007/BF00315413](https://doi.org/10.1007/BF00315413) | [2127569](https://pubmed.ncbi.nlm.nih.gov/2127569) | The abstract provides specific quantitative values for total body clearance, S/R clearance ratios, and half-life ratios for tocainide enantiomers in humans. |
| `Rice_1989.pdf` | Rice TL et al., Influence of rifampin on tocainide phar…, Clinical pharmacy (1989) | popPK | 10 | not captured | [2495879](https://pubmed.ncbi.nlm.nih.gov/2495879) | The study reports quantitative PK parameters (elimination rate constant, half-life, AUC) for tocainide in humans, with specific numeric values provided in the abstract. |
| `Wiegers_1983.pdf` | Wiegers U et al., Pharmacokinetics of tocainide in patien…, European journal of clinica… (1983) | popPK | 10 | [10.1007/BF00609893](https://doi.org/10.1007/BF00609893) | [6407848](https://pubmed.ncbi.nlm.nih.gov/6407848) | The abstract provides specific quantitative values for plasma half-life and total plasma clearance for tocainide in patients with renal dysfunction. |
| `Braun_1985.pdf` | Braun J et al., Pharmacokinetics of tocainide in patien…, European journal of clinica… (1985) | popPK | 9 | [10.1007/BF00607912](https://doi.org/10.1007/BF00607912) | [3933983](https://pubmed.ncbi.nlm.nih.gov/3933983) | The study reports pharmacokinetic parameters for tocainide in humans, but the evidence only provides peak plasma concentrations (Cmax) and qualitative descriptions of clearance, lacking specific numeric values for CL, V, or half-life. |
| `Oltmanns_1983.pdf` | Oltmanns D et al., Pharmacokinetics of tocainide in patien…, European journal of clinica… (1983) | popPK | 9 | [10.1007/BF00542521](https://doi.org/10.1007/BF00542521) | [6420165](https://pubmed.ncbi.nlm.nih.gov/6420165) | The study reports quantitative pharmacokinetic parameters (half-life, clearance, volume of distribution) for tocainide in human patients with hepatic and renal dysfunction. |
| `Venkataramanan_1980.pdf` | Venkataramanan R et al., The effect of phenobarbital and SKF 525…, The Journal of pharmacology… (1980) | popPK | 9 | not captured | [6778991](https://pubmed.ncbi.nlm.nih.gov/6778991) | The study reports quantitative PK parameters (clearance, AUC, excretion) for tocainide in rats, but the specific numeric values are not present in the provided abstract text. |
| `Christensen_1995_2.pdf` | Christensen EB et al., Assay of tocainide enantiomers in plasm…, Journal of chromatography.… (1995) | popPK | 8 | [10.1016/0378-4347(95)00183-2](https://doi.org/10.1016/0378-4347(95)00183-2) | [8548014](https://pubmed.ncbi.nlm.nih.gov/8548014) | The study reports pharmacokinetic parameters for tocainide in rabbits, but the specific numeric values are not present in the provided evidence text. |
| `Elvin_1980.pdf` | Elvin AT et al., Tocainide kinetics and metabolism: effe…, Clinical pharmacology and t… (1980) | popPK | 8 | [10.1038/clpt.1980.217](https://doi.org/10.1038/clpt.1980.217) | [6777107](https://pubmed.ncbi.nlm.nih.gov/6777107) | The study reports quantitative PK parameters (AUC, urinary excretion percentages) for tocainide in humans, but does not explicitly list clearance (CL) or volume (V) values. |
| `Klein_1980.pdf` | Klein MD et al., Antiarrhythmic efficacy, pharmacokineti…, Chest (1980) | popPK | 8 | [10.1378/chest.77.6.726](https://doi.org/10.1378/chest.77.6.726) | [6772381](https://pubmed.ncbi.nlm.nih.gov/6772381) | The study reports the plasma half-time of elimination (19.1 +/- 6.8 hours) for tocainide in humans, but lacks other quantitative disposition parameters like clearance or volume of distribution. |
| `North_1988.pdf` | North DS et al., The effect of histamine-2 receptor anta…, Journal of clinical pharmac… (1988) | popPK | 8 | [10.1002/j.1552-4604.1988.tb03188.x](https://doi.org/10.1002/j.1552-4604.1988.tb03188.x) | [2905709](https://pubmed.ncbi.nlm.nih.gov/2905709) | The study reports quantitative PK parameters (AUC, Cmax, renal clearance, half-life) for tocainide in humans, though specific numeric values for clearance and half-life are not explicitly listed in the text provided. |
| `Runciman_1987.pdf` | Runciman WB et al., The effects of general anaesthesia on t…, Xenobiotica; the fate of fo… (1987) | popPK | 8 | [10.3109/00498258709043989](https://doi.org/10.3109/00498258709043989) | [3660850](https://pubmed.ncbi.nlm.nih.gov/3660850) | The study reports quantitative changes in tocainide clearance (50% reduction) and extraction ratios in sheep, but specific baseline numeric values for CL or V are not explicitly listed in the provided text. |
| `Venkataramanan_1980_2.pdf` | Venkataramanan R et al., Dose-dependent pharmacokinetics of toca…, The Journal of pharmacology… (1980) | popPK | 8 | not captured | [6778990](https://pubmed.ncbi.nlm.nih.gov/6778990) | The study reports qualitative pharmacokinetic findings (nonlinear kinetics, absorption) for tocainide in rats, but specific numeric parameter values (CL, V, t1/2) are not present in the provided evidence. |
| `Follath_1983.pdf` | Follath F et al., Reliability of antiarrhythmic drug plas…, Clinical pharmacokinetics (1983) | pd | 5 | [10.2165/00003088-198308010-00004](https://doi.org/10.2165/00003088-198308010-00004) | [6404580](https://www.ncbi.nlm.nih.gov/pubmed/6404580) | metadata signals extractable PD data (concentration-effect) |
| `Meffin_1977.pdf` | Meffin PJ et al., Response optimization of drug dosage: a…, Clinical pharmacology and t… (1977) | pd | 5 | [10.1002/cpt197722142](https://doi.org/10.1002/cpt197722142) | [872495](https://www.ncbi.nlm.nih.gov/pubmed/872495) | metadata signals extractable PD data (concentrationeffect) |
| `Almotrefi_1991.pdf` | Almotrefi AA et al., The effect of modifying potassium conce…, General pharmacology (1991) | pd | 4 | [10.1016/0306-3623(91)90584-s](https://doi.org/10.1016/0306-3623(91)90584-s) | [1667301](https://www.ncbi.nlm.nih.gov/pubmed/1667301) | metadata signals extractable PD data (IC50) |
| `De_1995.pdf` | De Luca A et al., Stereoselective effects of mexiletine e…, Naunyn-Schmiedeberg's archi… (1995) | pd | 4 | [10.1007/BF00171325](https://doi.org/10.1007/BF00171325) | [9053738](https://www.ncbi.nlm.nih.gov/pubmed/9053738) | metadata signals extractable PD data (IC50) |
| `Dzimiri_1991.pdf` | Dzimiri N et al., Comparative effects of procainamide, to…, General pharmacology (1991) | pd | 4 | [10.1016/0306-3623(91)90472-i](https://doi.org/10.1016/0306-3623(91)90472-i) | [1647350](https://www.ncbi.nlm.nih.gov/pubmed/1647350) | metadata signals extractable PD data (IC50) |
| `Dzimiri_1993.pdf` | Dzimiri N, Effects of procainamide, tocainide and…, Research communications in… (1993) | pd | 4 | not captured | [8488338](https://www.ncbi.nlm.nih.gov/pubmed/8488338) | metadata signals extractable PD data (IC50) |
| `Hill_1988.pdf` | Hill RJ et al., Determinants of stereospecific binding…, Molecular pharmacology (1988) | pd | 4 | not captured | [2848186](https://www.ncbi.nlm.nih.gov/pubmed/2848186) | metadata signals extractable PD data (IC50) |
| `Honerjäger_1986.pdf` | Honerjäger P et al., Negative inotropic effects of tetrodoto…, Naunyn-Schmiedeberg's archi… (1986) | pd | 4 | [10.1007/BF00511411](https://doi.org/10.1007/BF00511411) | [2422563](https://www.ncbi.nlm.nih.gov/pubmed/2422563) | metadata signals extractable PD data (IC50) |
| `Sheldon_1988.pdf` | Sheldon RS et al., Stereospecific interaction of tocainide…, Molecular pharmacology (1988) | pd | 4 | not captured | [2451117](https://www.ncbi.nlm.nih.gov/pubmed/2451117) | metadata signals extractable PD data (IC50) |
| `Sheldon_1994.pdf` | Sheldon RS et al., Class I antiarrhythmic drugs: allosteri…, The Journal of pharmacology… (1994) | pd | 4 | not captured | [8301556](https://www.ncbi.nlm.nih.gov/pubmed/8301556) | metadata signals extractable PD data (IC50) |

<sub>queue written 2026-10-06T05:02:48.573703+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| PD | Adams_1986 | not_relevant | 1 | 0 | The text is a qualitative review of the pharmacodynamic classification of antiarrhythmic drugs and does not report any numeric PD parameters or exposure-response data for tocainide. |
| popPK | Braun_1985 | relevant | 9 | 2 | The study reports pharmacokinetic parameters for tocainide in humans, but the evidence only provides peak plasma concentrations (Cmax) and qualitative descriptions of clearance, lacking specific numeric values for CL, V, or half-life. |
| PD | Brogden_1987 | not_relevant | 1 | 0 | The text is a qualitative review of disopyramide that mentions tocainide only as a comparator in efficacy trials, without providing any numeric PD parameters or exposure-response data for tocainide. |
| popPK | Carocci_2018 | irrelevant | 1 | 0 | The paper is a review focused on synthesis and analogues, and the provided evidence contains no quantitative pharmacokinetic parameter values for tocainide. |
| PD | Cheshire_1997 | not_relevant | 0 | 0 | The text is a clinical review of drug choices for trigeminal neuralgia and mentions tocainide only in the context of adverse effects (aplastic anaemia), providing no pharmacodynamic or exposure-response data. |
| popPK | Christensen_1995 | irrelevant | 2 | 2 | The study reports myocardial tissue accumulation kinetics in an isolated organ system, not systemic population pharmacokinetic parameters (CL, V, Q) for the drug in a whole organism. |
| popPK | Christensen_1995_2 | relevant | 8 | 0 | The study reports pharmacokinetic parameters for tocainide in rabbits, but the specific numeric values are not present in the provided evidence text. |
| popPK | De_2004 | irrelevant | 0 | 0 | The study evaluates the antimyotonic efficacy of tocainide and its analogues in mice, reporting pharmacodynamic outcomes (righting reflex time) rather than quantitative pharmacokinetic parameters (CL, V, etc.). |
| popPK | Denaro_1989 | irrelevant | 0 | 0 | The paper is a review of toxicity and adverse effects of class 1B antiarrhythmics, not a pharmacokinetic study reporting quantitative disposition parameters for tocainide. |
| PD | Follath_1983 | not_relevant | 1 | 0 | The text is a qualitative review discussing the reliability of therapeutic drug monitoring and concentration-effect relationships for antiarrhythmics, including tocainide, but it does not present any specific numeric PD parameters, data, or curves. |
| PD | Gillis_1994 | not_relevant | 2 | 1 | The study reports qualitative comparisons of electrophysiological effects at a single fixed concentration (or unspecified perfusion conditions) between two dietary groups, without providing dose-response curves, Emax/EC50 parameters, or a formal PK/PD model for tocainide. |
| PD | Harron_1987 | not_relevant | 1 | 0 | The text is a review of propafenone that only qualitatively mentions tocainide in a comparative efficacy context without providing any numeric PD parameters or exposure-response data for tocainide. |
| popPK | Hasegawa_1985 | irrelevant | 2 | 0 | The text is a clinical review/overview that mentions a half-life range but lacks specific quantitative PK parameters (CL, V, ka) or a compartmental model required for extraction. |
| PD | Holmes_1985 | not_relevant | 1 | 0 | The text is a qualitative review of flecainide that mentions tocainide only for comparative efficacy, providing no numeric PD parameters or exposure-response data for tocainide. |
| popPK | Kutalek_1985 | irrelevant | 2 | 1 | The text is a general overview/review of tocainide's clinical profile and efficacy, lacking specific quantitative population pharmacokinetic parameters (CL, V, Q) or compartmental models. |
| popPK | Lucas_1990 | irrelevant | 1 | 0 | The paper is a review discussing electrophysiology and general pharmacology without reporting specific quantitative pharmacokinetic parameter values for tocainide. |
| PD | Lüderitz_1991 | not_relevant | 1 | 0 | The text is a general review of antiarrhythmic therapy that mentions tocainide only as a new substance without providing any specific pharmacodynamic data, exposure-response relationships, or numeric parameters. |
| popPK | Mehvar_2002 | irrelevant | 1 | 0 | The paper is a review discussing stereoselectivity in antiarrhythmics and mentions tocainide only qualitatively without providing any original quantitative pharmacokinetic parameter values. |
| PD | Mehvar_2002 | not_relevant | 1 | 0 | The text is a qualitative review discussing stereoselectivity in PK and PD of antiarrhythmics, including tocainide, but provides no numeric PD parameters, concentration-effect curves, or specific dose-response data. |
| PD | Mohiuddin_1983 | not_relevant | 1 | 0 | The paper reports PK parameters and notes that plasma concentrations did not correlate with clinical response, failing to provide any numeric PD parameters or exposure-response relationship. |
| PD | Morganroth_1985 | not_relevant | 1 | 0 | The text is a qualitative review summary discussing efficacy and side effects without providing any numeric concentration-effect data, dose-response curves, or PD parameters. |
| PD | Muraglia_2014 | not_relevant | 3 | 2 | The paper reports qualitative structure-activity relationships and identifies a candidate compound with a favorable profile, but does not provide numeric PD parameters (e.g., IC50, Emax) or extractable concentration-effect curves in the provided text. |
| popPK | Pottage_1983 | irrelevant | 0 | 0 | The paper is a qualitative review of clinical profiles and does not report specific quantitative pharmacokinetic parameter values for tocainide. |
| popPK | Runciman_1987 | relevant | 8 | 2 | The study reports quantitative changes in tocainide clearance (50% reduction) and extraction ratios in sheep, but specific baseline numeric values for CL or V are not explicitly listed in the provided text. |
| PD | Runciman_1987 | not_relevant | 1 | 0 | The paper reports pharmacokinetic changes (clearance, extraction ratio) and qualitative haemodynamic observations, but does not provide numeric pharmacodynamic parameters (e.g., Emax, EC50) or a quantitative concentration-effect relationship for tocainide. |
| PD | Tejerina_1983 | not_relevant | 2 | 1 | The paper describes qualitative dose-dependent effects of tocainide in an isolated organ bath study but does not provide numeric PD parameters (e.g., EC50, Emax) or extractable concentration-effect curves for tocainide. |
| popPK | Venkataramanan_1980 | relevant | 9 | 2 | The study reports quantitative PK parameters (clearance, AUC, excretion) for tocainide in rats, but the specific numeric values are not present in the provided abstract text. |
| popPK | Venkataramanan_1980_2 | relevant | 8 | 2 | The study reports qualitative pharmacokinetic findings (nonlinear kinetics, absorption) for tocainide in rats, but specific numeric parameter values (CL, V, t1/2) are not present in the provided evidence. |
| PGx | Wei_1999 | not_relevant | 0 | 0 | The study investigates the in vitro inhibition of CYP1A2 by tocainide but does not report any pharmacogenomic effects (gene variants) on tocainide's PK or PD parameters. |
| popPK | Woosley_1986 | irrelevant | 0 | 0 | The paper is a general review discussing the effects of CHF on antiarrhythmic agents and mentions tocainide only as an example of an agent with minimal myocardial depression, without providing specific quantitative PK parameters for it. |
| PD | Woosley_1986 | not_relevant | 1 | 0 | The text is a qualitative review discussing general PK changes in CHF and mentions tocainide's minimal myocardial depression without providing any numeric PD parameters or concentration-effect data. |
| popPK | Woosley_1987 | irrelevant | 0 | 0 | The text is a general review discussing pharmacokinetic principles in CHF and mentions tocainide only as an example of an agent with minimal myocardial depression, without reporting any specific quantitative PK parameters for it. |
| PD | Woosley_1987 | not_relevant | 1 | 0 | The text is a qualitative review of PK/PD considerations in CHF and mentions tocainide only in the context of minimal myocardial depression without providing any numeric PD parameters or concentration-effect data. |
| popPK | Woosley_1990 | irrelevant | 1 | 0 | The paper is a conceptual review discussing stereochemistry and pharmacogenetics without reporting original quantitative PK parameter values for tocainide. |
| PGx | Woosley_1990 | not_relevant | 2 | 0 | The text is a conceptual review mentioning pharmacogenetics and stereoisomer clearance differences generally, but it does not report specific gene variants or quantitative pharmacogenomic effect sizes for tocainide. |
| PD | Zrenner_1990 | not_relevant | 0 | 0 | The text is a review of clinical trial outcomes (mortality rates) for anti-arrhythmic drugs, including tocainide, and does not contain any pharmacokinetic or pharmacodynamic modeling, concentration-effect data, or numeric PD parameters. |

---
<sub>Generated by `docs.py` (scholarv2) · newest extraction 2026-10-06 05:03 UTC</sub>
